TRANSACTIONS

OUR TRANSACTIONS HELP IDENTIFY, FOSTER AND CREATE INVESTMENT OPPORTUNITIES IN THE HEALTHCARE SECTOR, ON BEHALF OF COMPANIES AND INVESTORS

FILTER BY

>
Service
>
  • Company Creation

  • Raising Capital & Financing - Equity

  • Raising Capital & Financing - Debt

  • Merger & Acquisition Advisory

  • Monetization Planning

  • Sector
    >
  • Medical Devices and Diagnostics

  • Healthcare IT

  • Healthcare Services

  • Therapeutics

  • Stage
    >
  • Commercial Stage

  • Development Stage

  • X

    CAD

    $1000,395,000

    CannTrust

    BOUGHT DEAL, JUNE 2018

    X

    US $48,990,000

    ESSA Pharma Inc.

    PUBLIC OFFERING
    JULY 2020

    HOUSTON and VANCOUVER, BC, July 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritten public offering of 7,100,000 common shares of the Company at a public offering price of US$6.00 per share, before underwriting discounts, for an aggregate offering of approximately US$42.6 million (the "Offering"). ESSA granted the underwriters a 30-day option to purchase up to an additional 1,065,000 common shares (the "Option"), and the underwriters exercised the Option on July 29, 2020. The proceeds to ESSA from the Offering, including the exercise of the Option, were approximately US$45.0 million after deducting underwriting discounts and commissions (such commission being equal to 6% of the aggregate gross proceeds of the Offering) and other estimated offering expenses. Existing investors participated in the financing along with new investors Pfizer Inc. (NYSE: PFE), Avidity Partners, CAM Capital, Point72, Ridgeback Capital, Sphera Healthcare and Vivo Capital.

    Press Release
    X

    CAD $28,750,000

    Antibe Therapeutics Inc.

    BOUGHT DEAL
    JUNE 2020

    Toronto, Ontario--(Newsfile Corp. - June 30, 2020) - Antibe Therapeutics Inc. (TSXV: ATE) ("Antibe" or the "Company") announced that it closed its previously announced bought deal public offering of 62,500,000 units of the Company (the "Units") at a price of $0.40 per Unit (the "Offering Price") plus the exercise in full of the Underwriters' over-allotment option of 9,375,000 units for aggregate gross proceeds of $28,750,000 (the "Offering"). The Offering was made pursuant to an underwriting agreement dated June 15, 2020 with a syndicate of underwriters led by Bloom Burton Securities Inc., together with Echelon Wealth Partners Inc., Paradigm Capital Inc., Raymond James Ltd., Stifel GMP and Industrial Alliance Securities Inc. (collectively, the "Underwriters").

    Press Release
    X

    CAD $15,525,000

    Appili Therapeutics Inc.

    PUBLIC OFFERING
    JUNE 2020

    Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”) announced the closing of its previously announced public offering (the “Public Offering”) of units (the “Units”). The Public Offering was made pursuant to an agency agreement entered into with a syndicate of agents led by Bloom Burton Securities Inc. (the “Lead Agent”) and including Mackie Research Capital Corporation, Industrial Alliance Securities Inc., Haywood Securities Inc., and Richardson GMP Limited (collectively with the Lead Agent, the “Agents”) and the Company.

    Press Release
    X

    CAD $15,000,000

    Greenbrook TMS

    PUBLIC OFFERING
    MAY 2020

    TORONTO, ON, May 21, 2020 – Greenbrook TMS Inc. (“Greenbrook” or the “Company”) (TSX: GTMS) is pleased to announce the closing of its previously announced public offering (the “Offering”) of common shares of the Company (the “Offered Shares”). The Offering was made pursuant to an agency agreement (the “Agency Agreement”) entered into among Bloom Burton Securities Inc. and Clarus Securities Inc., as co-lead agents, Canaccord Genuity Corp., Desjardins Securities Inc. and Stifel GMP (collectively, the “Agents”).

    Press Release
    X

    CAD $56,000,000

    adMare BioInnovations

    MERGER & ACQUISTION ADVISORY
    MARCH 2020

    X

    CAD $40,250,000

    Medicenna Therapeutics Corp.

    PUBLIC OFFERING
    MARCH 2020

    X

    CAD $10,250,000

    Appili Therapeutics Inc.

    PUBLIC OFFERING
    FEBRUARY 2020

    X

    Aurinia Pharmaceuticals

    MONETIZATION PLANNING
    JANUARY 2020

    X

    US $116,955,000

    Trillium Therapeutics Inc.

    Public Offering
    JANUARY 2020

    X

    US $ 60,000,000

    Xenon Pharmaceuticals Inc.

    Public Offering
    JANUARY 2020

    X

    Neoleukin Therapeutics

    MONETIZATION PLANNING
    DECEMBER 2019

    X

    US $191,700,000

    Aurinia Pharmaceuticals

    PUBLIC OFFERING
    DECEMBER 2019

    X

    CAD $3,000,000

    Klinik Health Ventures Corp.

    IPO
    DECEMBER 2019

    X

    CAD $18,000,000

    BEACON™

    SERIES A FOLLOW-ON
    NOVEMBER 2019

    X

    CAD $6,900,000

    Medicenna Therapeutics Corp.

    PUBLIC OFFERING
    OCTOBER 2019

    X

    US $79,374,102

    Bellus Health

    U.S. IPO
    SEPTEMBER 2019

    X

    US $36,000,000

    ESSA Pharma Inc.

    PUBLIC OFFERING; PRIVATE PLACEMENT
    AUGUST 2019

    X

    US $35,000,000

    Titan Medical Inc.

    COMMON SHARE PURCHASE AGREEMENT
    AUGUST 2019

    X

    CAD $8,050,000

    Antibe Therapeutics Inc.

    PUBLIC OFFERING
    AUGUST 2019

    X

    CAD $15,200,000

    Resverlogix Corp.

    EQUITY OFFERING
    JUNE 2019

    X

    CAD $50,025,008

    HLS Therapeutics Inc.

    BOUGHT DEAL
    JUNE 2019

    X

    CAD $30,579,250

    Greenbrook TMS

    BOUGHT DEAL; PRIVATE PLACEMENT
    MAY 2019

    X

    CAD $5,260,000

    Avivagen

    PRIVATE PLACEMENT
    MARCH 2019

    X

    US $28,750,000

    Titan Medical Inc.

    PUBLIC OFFERING
    MARCH 2019

    X

    CAD $3,586,813

    Appili Therapeutics Inc.

    PRIVATE PLACEMENT
    MARCH 2019

    X

    Aurinia Pharmaceuticals

    MONETIZATION PLANNING
    FEBRUARY 2019

    X

    US $110,000,000

    Nuvo Pharmaceuticals Inc.

    MERGER & ACQUISTION ADVISORY
    DECEMBER 2018

    X

    CAD $4,000,000

    Medicenna Therapeutics Corp.

    Public Offering
    DECEMBER 2018

    X

    CAD $35,000,000

    Bellus Health

    EQUITY OFFERING
    DECEMBER 2018

    X

    Aurinia Pharmaceuticals

    MONETIZATION PLANNING
    OCTOBER 2018

    X

    UP TO CAD $88,000,000

    Pediapharm Inc.

    Merger & Acquisition Advisory
    OCTOBER 2018

    X

    US $ 63,000,000

    Xenon Pharmaceuticals Inc.

    Public Offering
    SEPTEMBER 2018

    X

    CAD $9,150,000

    LED Medical Diagnostics Inc.

    Private Placement
    SEPTEMBER 2018

    X

    CAD $10,000,000

    Hamilton Thorne Ltd.

    BOUGHT DEAL; PRIVATE PLACEMENT
    AUGUST 2018

    X

    US $19,198,935

    Titan Medical Inc.

    PUBLIC OFFERING
    AUGUST 2018

    X

    CAD $16,000,000

    Mimi's Rock

    DEBT FINANCING
    JULY 2018

    X

    CAD $17,400,000

    Mimi's Rock

    PRIVATE PLACEMENT
    JULY 2018

    X

    U.S. R&D Institute

    MONETIZATION PLANNING
    JUNE 2018

    X

    US $20,000,000

    Greenbrook TMS

    PRIVATE PLACEMENT
    JUNE 2018

    X

    Multinational Pharmaceutical Company

    MONETIZATION PLANNING
    MAY 2018

    X

    Multinational Pharmaceutical Company

    MONETIZATION PLANNING
    MAY 2018

    X

    CAD $6,184,647

    Kneat Software

    PRIVATE PLACEMENT
    APRIL 2018

    X

    CAD $10,139,988

    Titan Medical Inc.

    PUBLIC OFFERING
    APRIL 2018

    X

    CAD $27,797,275

    Sunniva Inc.

    BOUGHT DEAL; PUBLIC OFFERING
    MARCH 2018

    X

    CAD $14,375,000

    Immunovaccine Inc.

    BOUGHT DEAL
    FEBRUARY 2018

    X

    Satellos Bioscience Inc.

    Company Creation
    2018

    Satellos is a private, Canadian-based regenerative medicine company formed in 2018. The initial focus of the company is muscle regeneration, with a lead program in Duchenne Muscular Dystrophy.

    Press Release
    X

    US $26,040,000

    ESSA Pharma Inc.

    PUBLIC OFFERING
    JANUARY 2018

    X

    Precision Nutrition

    MERGER & ACQUISTION ADVISORY
    DECEMBER 2017

    X

    CAD $20,000,000

    Bellus Health

    PUBLIC EQUITY OFFERING
    DECEMBER 2017

    X

    CAD $23,000,000

    Titan Medical Inc.

    PUBLIC OFFERING
    DECEMBER 2017

    X

    CAD $4,000,000

    Avivagen

    PRIVATE PLACEMENT
    NOVEMBER 2017

    X

    CAD $8,925,000

    Titan Medical Inc.

    PUBLIC OFFERING
    JUNE 2017

    X

    CAD $4,983,000

    Antibe Therapeutics Inc.

    PUBLIC OFFERING
    JUNE 2017

    X

    CAD $10,000,000

    Resverlogix Corp.

    PUBLIC OFFERING
    JUNE 2017

    X

    TechAlliance of Southwestern Ontario

    MONETIZATION PLANNING
    APRIL 2017

    X

    EUR €13,900,000

    Hamilton Thorne Ltd.

    MERGER & ACQUISTION ADVISORY
    APRIL 2017

    X

    CAD $12,500,000

    Hamilton Thorne Ltd.

    PRIVATE PLACEMENT
    APRIL 2017

    X

    Weed MD

    MONETIZATION PLANNING
    MAY 2017

    X

    Alberta Innovates

    MONETIZATION PLANNING
    MAY 2017

    X

    NeuPath Health

    Company Creation
    2017

    NeuPath is Canada's largest provider of chronic pain services. Through their network and brands, NeuPath is constantly expanding the scope of their services to serve communities.

    Press Release
    X

    CAD $7,500,000

    Titan Medical Inc.

    PUBLIC OFFERING
    MARCH 2017

    X

    Alberta Innovates

    MONETIZATION PLANNING
    MARCH 2017

    X

    Aquinox Pharmaceuticals Inc.

    MONETIZATION PLANNING
    MARCH 2017

    X

    CAD $4,000,000

    Medicenna Therapeutics Corp.

    Private Placement
    March 2017

    X

    CAD $14,400,000

    LED Medical Diagnostics Inc.

    Private Placement
    February 2017

    X

    US $10,250,000

    LED Medical Diagnostics Inc.

    MERGER & ACQUISITION ADVISORY
    FEBRUARY 2017

    X

    CAD $100,050,000

    Knight Therapeutics Inc.

    Bought Deal
    December 2016

    X

    CAD $10,000,000

    Medicenna Therapeutics Corp.

    Private Placement
    December 2016

    X

    CAD $5,004,000

    CannaRoyalty Corp.

    Private Placement
    OCTOBER 2016

    X

    CAD $10,000,000

    Newtopia Inc.

    Series A Financing
    OCTOBER 2016

    X

    CAD $11,428,000

    Titan Medical Inc.

    Public Offering
    OCTOBER 2016

    X

    CAD $6,000,000

    Red Leaf Medical Inc.

    MERGER & ACQUISITION ADVISORY
    SEPTEMBER 2016

    X

    Bellus Health Inc.

    MONETIZATION PLANNING
    SEPTEMBER 2016

    X

    Clementia Pharmaceuticals

    MONETIZATION PLANNING
    SEPTEMBER 2016

    X

    Response Biomedical Corp.

    MERGER & ACQUISITION ADVISORY
    AUGUST 2016

    X

    US $107,000,000

    Noden Pharma Inc.

    Private Placement
    JULY 2016

    X

    Noden Pharma Inc.

    MERGER & ACQUISITION ADVISORY
    JULY 2016

    X

    Medicago Inc.

    MONETIZATION PLANNING
    JULY 2016

    X

    CAD $230,000,000

    Knight Therapeutics Inc

    Bought Deal
    JUNE 2016

    X

    CAD $15,000,000

    Titan Medical Inc.

    Public Offering
    APRIL 2016

    X

    Canadian Public Pharmaceutical Company

    Valuation Opinion
    MARCH 2016

    X

    CAD $82,980,000

    Nuvo Reserach Inc.

    Fairness Opinion
    MARCH 2016

    X

    CAD $12,080,000

    Titan Medical Inc.

    Private Offering
    FEBRUARY 2016

    X

    Medicenna Therapeutics Corp.

    MONETIZATION PLANNING
    FEBRUARY 2016

    X

    US $148,000,000

    Tribute Pharmaceuticals Canada Inc.

    Merger & Acquisition Advisory
    FEBRUARY 2016

    X

    Canadian Public Biotech Company

    MERGER & ACQUISITION ADVISORY
    JANUARY 2016

    X

    CAD $12,300,000

    INTEGA Skin Sciences Inc.

    Debt
    JANUARY 2016

    X

    US $15,000,000

    ESSA Pharma Inc.

    Private Placement
    JANUARY 2016

    X

    Appili Therapeutics Inc.

    Company Creation
    2015

    Appili Therapeutics Inc. was founded to advance the global fight against infectious disease by matching clearly defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors, and society face in this critical disease space.

    Press Release
    X

    Grey Wolf Animal Health Inc.

    Company Creation
    2015

    Grey Wolf Animal Health is a specialty animal health company focused on improving the lives and well-being of vets and pets in Canada and abroad. Founded in 2015 by Dr. Ian Sandler, their mission is to identify and bring to market products, solutions and services that meet the underserved needs of vets, pets and clinics across Canada.

    Press Release
    X

    Triumvira Immunologics Inc.

    Company Creation
    2015

    Triumvira is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.

    Press Release
    X

    Medicago Inc.

    Monetization Planning
    NOVEMBER 2015

    X

    CAD $2,120,000

    LED Medical Diagnostics Inc.

    Public Offering
    NOVEMBER 2015

    X

    CAD $47,000,000

    Alveda Pharmaceuticals Inc.

    Merger & Acquisition Advisory
    NOVEMBER 2015

    X

    Arthritis Innovation Corporation

    Valuation Opinion
    October 2015

    X

    US $200,000,000

    HLS Therapeutics Inc.

    Private Placement
    AUGUST 2015

    X

    US $185,000,000

    HLS Therapeutics Inc.

    Syndicated Loan
    AUGUST 2015

    X

    Exerkine Corporation

    Merger & Aquisition Advisory
    AUGUST 2015

    X

    CAD $1,590,000

    Diagnos Inc.

    Private Placement
    JULY 2015

    X

    CAD $2,680,000

    Agility Health Inc.

    Public Offering
    JUNE 2015

    X

    CAD $4,020,000

    Medicure Inc.

    Bought Deal; Private Placement
    JUNE 2015

    X

    CAD $12,500,000

    Tribute Pharmaceuticals Canada Inc.

    Private Placement
    JUNE 2015

    X

    CAD $25,000,000

    Medical Futures Inc.

    Merger & Acquisition Advisory
    JUNE 2015

    X

    CAD $12,000,000

    Tribute Pharmaceuticals Canada Inc.

    Raising Capital & Financing
    MAY 2016

    X

    US $55,150,000

    Trillium Therapeutics Inc.

    Public Offering
    APRIL 2015

    X

    CAD $24,010,000

    Profound Medical Corp.

    Private Placement
    APRIL 2015

    X

    CAD $5,500,000

    Pediapharm Inc.

    Private Placement
    MARCH 2015

    X

    CAD $27,370,000

    CRH Medical Corporation

    Bought Deal
    MARCH 2015

    X

    Qing Bile Therapeutics Inc.

    Company Creation
    2015

    Qing Bile Therapeutics is a preclinical stage, private Canadian biotechnology company founded in 2015 based on research from Dr. Victor Ling’s laboratory at the University of British Columbia and BC Cancer Agency. Qing Bile has identified tetrahydroxylated bile acids (THBAs) to treat cholestatic and metabolic diseases with high unmet need.

    Press Release
    X

    Ontario Academic Institution

    Monetization Planning
    JANUARY 2015

    X

    Xenon Pharmaceuticals Inc.

    Monetization Planning
    JANUARY 2015

    X

    US $12,000,000

    ESSA Pharma Inc.

    Private Placement
    JANUARY 2015

    X

    Pharmascience Inc.

    Monetization Planning
    JANUARY 2015

    X

    CAD $100,000,000

    Knight Therapeutics Inc.

    Bought Deal
    DECEMBER 2014

    X

    US $52,000,000

    CRH Medical Corporation

    Debt
    DECEMBER 2014

    X

    US $73,200,000

    CRH Medical Corporation

    Merger & Acquisition Advisory
    DECEMBER 2014

    X

    CAD $1,350,000

    Essa Pharma Inc.

    Private Placement
    OCTOBER 2014

    X

    US $45,000,000

    Nuvo Research Inc.

    Merger & Acquisition Advisory
    OCTOBER 2014

    X

    iCo Therapeutics Inc.

    Monetization Planning
    OCTOBER 2014

    X

    TEC Edmonton

    Monetization Planning
    OCTOBER 2014

    X

    CAD $5,766,100

    Bioniche Life Sciences Inc.

    Private Placement
    SEPTEMBER 2014

    X

    CAD $3,400,000

    Essa Pharma Inc.

    Private Placement
    JULY 2014

    X

    CAD $30,026,500

    Tribute Pharmaceuticals Inc.

    Public Offering
    JULY 2014

    X

    Warnex Inc.

    MERGER & ACQUISITION ADVISORY
    MAY 2014

    X

    Plantform Corporation

    MONETIZATION PLANNING
    MAY 2014

    X

    McMaster University Faculty of Health Sciences

    MONETIZATION PLANNING
    MAY 2014

    X

    CAD $180,075,000

    Knight Therapeutics Inc.

    Private Placement
    APRIL 2014

    X

    CAD $3,400,000

    Agility Health Inc.

    Private Placement
    APRIL 2014

    X

    Antibe Therapeutics Inc.

    MONETIZATION PLANNING
    APRIL 2014

    X

    CAD $3,130,000

    Nuvo Research Inc.

    Private Placement
    APRIL 2014

    X

    Pediapharm Inc.

    Monetization Planning
    APRIL 2014

    X

    CPDC

    Monetization Planning
    MARCH 2014

    X

    CAD $3,020,000

    Antibe Therapeutics Inc.

    Raising Capital & Financing
    MARCH 2013

    X

    CAD $3,100,000

    Nuvo Pharmaceuticals Inc.

    Private Placement
    MARCH 2014

    X

    CAD $3,000,000

    Antibe Therapeutics Inc.

    Private Placement
    MARCH 2014

    X

    Bioniche Life Sciences Inc.

    MERGER & ACQUISITION ADVISORY
    MARCH 2014

    X

    Trillium Therapeutics Inc.

    MONETIZATION PLANNING
    MARCH 2014

    X

    Xenon Pharmaceuticals Inc.

    Monetization Planning
    FEBRUARY 2014

    X

    CAD $7,530,000

    Triton Pharma Inc.

    Mergers & Acquisition Advisory
    JANUARY 2014

    X

    CAD $33,000,000

    Stem Cell Therapeutics Corp.

    Private Placement
    DECEMBER 2013

    X

    Sirona Biochem Corp.

    MONETIZATION PLANNING
    OCTOBER 2013

    X

    Approx. CAD $17,000,000

    STI Technologies Ltd.

    Private Equity Investment
    SEPTEMBER 2013

    X

    CAD $9,804,500

    Bioniche Life Sciences Inc.

    Public Offering
    SEPTEMBER 2013

    X

    Up to CAD $4,000,000

    Response Biomedical Corp.

    Private Placement
    SEPTEMBER 2013

    X

    Approx. CAD $357,000,000

    Medicago Inc.

    MERGER & ACQUISITION ADVISORY
    SEPTEMBER 2013

    X

    CIMTEC

    MONETIZATION PLANNING
    SEPTEMBER 2013

    X

    Aquinox Pharmaceuticals Inc.

    MONETIZATION PLANNING
    SEPTEMBER 2013

    X

    US $6,000,000

    Tribute Pharmaceuticals Inc.

    Debt
    August 2013

    X

    Approx. CAD $13,000,000

    Thallion Pharmaceuticals Inc.

    MERGER & ACQUISITION ADVISORY
    August 2013

    X

    CAD $3,155,100

    Antibe Therapeutics Inc.

    Initial Public Offering
    JUNE 2013

    X

    CAD $3,379,520

    iCo Therapeutics Inc.

    Overnight Offering
    MAY 2013

    X

    CAD $40,000,000

    Trimel Pharmaceuticals Corp.

    Public Offering
    APRIL 2013

    X

    CAD $3,100,000

    Stem Cell Therapeutics Corp.

    Public Offering
    MARCH 2013

    X

    Victhom Human Bionics Inc.

    MERGER & ACQUISITION ADVISORY
    MARCH 2013

    X

    Tekmira Pharmaceuticals

    MONETIZATION PLANNING
    JANUARY 2013

    X

    CRH Medical Corp.

    MONETIZATION PLANNING
    JANUARY 2013

    X

    CAD $12,500,000

    Agility Health Inc.

    Private Placement
    DECEMBER 2012

    X

    Approx. US 510,000,000

    YM BioSciences Inc.

    MERGER & ACQUISITION ADVISORY
    DECEMBER 2012

    X

    Ontario Institute for Cancer Research

    MONETIZATION PLANNING
    DECEMBER 2012

    X

    Warnex Inc.

    MERGER & ACQUISITION ADVISORY
    OCTOBER 2012

    X

    CML Healthcare Inc.

    MONETIZATION PLANNING
    OCTOBER 2012

    X

    US $7,500,000

    Trimel Pharmaceuticals Corp.

    Venture debt
    JULY 2012

    X

    CAD $2,550,000

    iCo Therapeutics Inc.

    Overnight Offering
    JULY 2012

    X

    Pharmagap Inc.

    MERGER & ACQUISITION ADVISORY
    JULY 2012

    X

    Bellus Health Inc.

    MONETIZATION PLANNING
    JUNE 2012

    X

    Sirona Biochem Corp.

    MONETIZATION PLANNING
    JUNE 2012

    X

    Canadian Public Biotechnology Company

    MONETIZATION PLANNING
    JUNE 2012

    X

    CAD $8,000,000

    Nuvo Pharmaceuticals Inc.

    Secured Debt
    MAY 2012

    X

    US $6,000,000

    Stellar Pharmaceuticals Inc.

    Secured Debt
    MAY 2012

    X

    Patient Home Monitoring Corp.

    MONETIZATION PLANNING
    APRIL 2012

    X

    Antibe Therapeutics Inc.

    MONETIZATION PLANNING
    JANUARY 2012

    X

    CAD $448,231

    Microbix Biosystems Inc.

    Public Offering
    DECEMBER 2011

    X

    Approx. CAD $10,000,000

    Stellar Pharmaceuticals Inc.

    MERGER & ACQUISITION ADVISORY
    DECEMBER 2011

    X

    CAD $3,520,000

    Botaneco Inc.

    Private Placement
    OCTOBER 2011

    X

    CAD $10,000,000

    Allon Therapeutics Inc.

    Public Offering
    OCTOBER 2011

    X

    Advitech Inc.

    MERGER & ACQUISITION ADVISORY
    OCTOBER 2011

    X

    CAD $25,000,000

    Medicago Inc.

    Private Placement
    SEPTEMBER 2011

    X

    CAD $2,200,000

    Lorus Therapeutics Inc.

    Public Offering
    AUGUST 2011

    X

    CAD $12,600,000

    Resverlogix Corp.

    Overnight Offering
    JUNE 2011

    X

    Nuvo Pharmaceuticals Inc.

    MONETIZATION PLANNING
    JUNE 2011

    X

    CAD $717,500

    Microbix Biosystems Inc.

    Private Placement
    APRIL 2011

    X

    Miraculins Inc.

    MONETIZATION PLANNING
    APRIL 2011

    X

    CAD $17,399,976

    Medicago Inc.

    Overnight Offering
    MARCH 2011

    X

    CAD $2,000,000

    Stem Cell Therapeutics Corp.

    Overnight Offering
    MARCH 2011

    X

    CAD $40,250,000

    Paladin Labs Inc.

    Bought Deal
    FEBRUARY 2011

    X

    CAD $1,808,866

    Ventripoint Inc.

    Private Placement
    JANUARY 2011

    X

    CAD $46,000,000

    YM Biosciences Inc.

    Public Offering
    DECEMBER 2010

    X

    CAD$ 5,000,000

    Agility Health Inc.

    Term Debt Financing
    DECEMBER 2010

    X

    CAD $28,777,600

    Oncolytics Biotech Inc.

    Bought Deal
    OCTOBER 2010

    X

    CAD $7,465,100

    ImmunoVaccine Inc.

    Public Offering
    SEPTEMBER 2010

    X

    CAD $7,500,000

    Medicago Inc.

    Overnight Offering
    AUGUST 2010

    X

    Miraculins Inc.

    MERGER & ACQUISITION ADVISORY
    AUGUST 2010

    X

    CAD $10,000,000

    Resverlogix Corp.

    Overnight Offering
    JUNE 2010

    X

    CAD $5,000,000

    Patient Home Monitoring Corp.

    Equity Line
    JUNE 2010

    X

    CAD $9,200,000

    Resverlogix Corp.

    Overnight Offering
    JUNE 2010

    X

    CAD $4,500,000

    Patient Home Monitoring Corp.

    Private Placement
    JUNE 2010

    X

    Patient Home Monitoring Corp.

    MERGER & ACQUISITION ADVISORY
    JUNE 2010

    X

    Approx. CAD $7,000,000

    DiaMedica Inc.

    MERGER & ACQUISITION ADVISORY
    JUNE 2010

    X

    Cipher Pharmaceuticals Inc.

    MONETIZATION PLANNING
    JUNE 2010

    X

    Medicago Inc.

    MONETIZATION PLANNING
    JUNE 2010

    X

    CAD $10,000,000

    Medicago Inc.

    Equity Line
    MAY 2010

    X

    US $17,500,000

    YM Biosciences Inc.

    Registered Direct Offering
    MARCH 2010

    X

    Conjuchem LLC

    MERGER & ACQUISITION ADVISORY
    MARCH 2010

    X

    Approx. CAD $12,500,000

    YM Biosciences Inc.

    MERGER & ACQUISITION ADVISORY
    FEBRUARY 2010

    X

    CAD $8,000,000

    Resverlogix Corp.

    Private Placement
    JANUARY 2010

    X

    Medicure Inc.

    MERGER & ACQUISITION ADVISORY
    JANUARY 2010

    X

    CAD $25,000,000

    LaboPharm Inc.

    Equity Line
    NOVEMBER 2009

    X

    CAD $11,592,000

    Medicago Inc.

    Bought Deal
    NOVEMBER 2009

    X

    US $14,662,500

    Oncolytics Biotech Inc.

    Overnight Offering
    NOVEMBER 2009

    X

    CAD $750,000

    Patient Home Monitoring Corp.

    Private Placement
    OCTOBER 2009

    X

    CAD $1,500,000

    Chemaphor Inc.

    Private Placement
    APRIL 2009

    X

    DRM Ventures Inc.

    MERGER & ACQUISITION ADVISORY
    OCTOBER 2009

    X

    CAD $500,000

    Med BioGene Inc.

    Private Placement
    SEPTEMBER 2009

    X

    Bradmer Pharmaceuticals Inc.

    MERGER & ACQUISITION ADVISORY
    JULY 2009

    X

    CAD $58,700,000

    Paladin Labs Inc.

    Bought Deal
    JUNE 2009

    X

    Med BioGene Inc.

    MERGER & ACQUISITION ADVISORY
    June 2009

    X

    CAD $380,000

    Chemaphor Inc.

    Private Placement
    APRIL 2009